180 related articles for article (PubMed ID: 33903200)
1. CD40 Agonist Targeted to Fibroblast Activation Protein α Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors.
Labiano S; Roh V; Godfroid C; Hiou-Feige A; Romero J; Sum E; Rapp M; Boivin G; Wyss T; Simon C; Bourhis J; Umaña P; Trumpfheller C; Tolstonog GV; Vozenin MC; Romero P
Clin Cancer Res; 2021 Jul; 27(14):4054-4065. PubMed ID: 33903200
[TBL] [Abstract][Full Text] [Related]
2. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.
Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM
Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity.
Sum E; Rapp M; Fröbel P; Le Clech M; Dürr H; Giusti AM; Perro M; Speziale D; Kunz L; Menietti E; Brünker P; Hopfer U; Lechmann M; Sobieniecki A; Appelt B; Adelfio R; Nicolini V; Freimoser-Grundschober A; Jordaan W; Labiano S; Weber F; Emrich T; Christen F; Essig B; Romero P; Trumpfheller C; Umaña P
Clin Cancer Res; 2021 Jul; 27(14):4036-4053. PubMed ID: 33771854
[TBL] [Abstract][Full Text] [Related]
4. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
Huang SH; O'Sullivan B; Su J; Ringash J; Bratman SV; Kim J; Hosni A; Bayley A; Cho J; Giuliani M; Hope A; Spreafico A; Hansen AR; Siu LL; Gilbert R; Irish JC; Goldstein D; de Almeida J; Tong L; Xu W; Waldron J
Cancer; 2020 Aug; 126(15):3426-3437. PubMed ID: 32478895
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation.
Liu C; Sadat SH; Ebisumoto K; Sakai A; Panuganti BA; Ren S; Goto Y; Haft S; Fukusumi T; Ando M; Saito Y; Guo T; Tamayo P; Yeerna H; Kim W; Hubbard J; Sharabi AB; Gutkind JS; Califano JA
Clin Cancer Res; 2020 Jun; 26(11):2693-2703. PubMed ID: 31932491
[TBL] [Abstract][Full Text] [Related]
7. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
[TBL] [Abstract][Full Text] [Related]
8. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
[TBL] [Abstract][Full Text] [Related]
9. Effects of HPV Status on Responsiveness to Ionizing Radiation vs Photodynamic Therapy in Head and Neck Cancer Cell lines.
Kessel D; Cho WJ; Rakowski J; Kim HE; Kim HC
Photochem Photobiol; 2020 May; 96(3):652-657. PubMed ID: 31408910
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitization approaches for HPV-positive and HPV-negative head and neck squamous carcinomas.
Dok R; Bamps M; Glorieux M; Zhao P; Sablina A; Nuyts S
Int J Cancer; 2020 Feb; 146(4):1075-1085. PubMed ID: 31283004
[TBL] [Abstract][Full Text] [Related]
11. Tumor DNA-methylome derived epigenetic fingerprint identifies HPV-negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy.
Tawk B; Wirkner U; Schwager C; Rein K; Zaoui K; Federspil PA; Adeberg S; Linge A; Ganswindt U; Hess J; Unger K; Tinhofer I; Budach V; Lohaus F; Krause M; Guberina M; Stuschke M; Balermpas P; Rödel C; Grosu AL; Schäfer H; Zips D; Combs SE; Pigorsch S; Zitzelsberger H; Baumeister P; Kirchner T; Bewerunge-Hudler M; Weichert W; Hess J; Herpel E; Belka C; Baumann M; Debus J; Abdollahi A;
Int J Cancer; 2022 Feb; 150(4):603-616. PubMed ID: 34648658
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line.
Harris M; Wang XG; Jiang Z; Goldberg GL; Casadevall A; Dadachova E
Head Neck Oncol; 2011 Feb; 3(1):9. PubMed ID: 21314983
[TBL] [Abstract][Full Text] [Related]
13. The role of Glial cell derived neurotrophic factor in head and neck cancer.
Cao H; He Q; Eyben RV; Bloomstein J; Nambiar DK; Viswanathan V; Aggarwal S; Kwok S; Liang R; Koong AJ; Lewis JS; Kong C; Xiao N; Le QT
PLoS One; 2020; 15(2):e0229311. PubMed ID: 32084217
[TBL] [Abstract][Full Text] [Related]
14. Myeloid cell-targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell-mediated immunity.
Moreira D; Sampath S; Won H; White SV; Su YL; Alcantara M; Wang C; Lee P; Maghami E; Massarelli E; Kortylewski M
J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33232304
[TBL] [Abstract][Full Text] [Related]
15. HPV + HNSCC-derived exosomal miR-9 induces macrophage M1 polarization and increases tumor radiosensitivity.
Tong F; Mao X; Zhang S; Xie H; Yan B; Wang B; Sun J; Wei L
Cancer Lett; 2020 May; 478():34-44. PubMed ID: 32120025
[TBL] [Abstract][Full Text] [Related]
16. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD
Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479
[TBL] [Abstract][Full Text] [Related]
17. Integrin alpha 6 as a stemness driver is a novel promising target for HPV (+) head and neck squamous cell carcinoma.
An JS; Moon JH; Kim C; No JK; Eun YG; Chang Lim Y
Exp Cell Res; 2021 Oct; 407(2):112815. PubMed ID: 34496296
[TBL] [Abstract][Full Text] [Related]
18.
Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
[TBL] [Abstract][Full Text] [Related]
19. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
[TBL] [Abstract][Full Text] [Related]
20. PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models.
Hernandez AL; Young CD; Bian L; Weigel K; Nolan K; Frederick B; Han G; He G; Devon Trahan G; Rudolph MC; Jones KL; Oweida AJ; Karam SD; Raben D; Wang XJ
Clin Cancer Res; 2020 Jun; 26(12):3058-3070. PubMed ID: 32139402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
